Summary
Donald Trump's announcement of up to 200% tariffs on pharmaceutical imports led to a selloff in Indian pharma stocks, but analysts suggest the long-term impact may be limited. This is attributed to India's manufacturing cost advantage, US-based production facilities of some drugmakers, and uncertainty regarding tariff implementation.